Cytokine and autoantibody clusters interaction in systemic lupus erythematosus

Background: Evidence supports the existence of different subphenotypes in systemic lupus erythematosus (SLE) and the pivotal role of cytokines and autoantibodies, which interact in a highly complex network. Thus, understanding how these complex nonlinear processes are connected and observed in real-...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2017
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/22483
Acceso en línea:
https://doi.org/10.1186/s12967-017-1345-y
https://repository.urosario.edu.co/handle/10336/22483
Palabra clave:
Alpha interferon
Autoantibody
Biological marker
Cytokine
Cytokine antibody
Double stranded dna antibody
Granulocyte colony stimulating factor
Phospholipid antibody
Antinuclear antibody
Autoantibody
Cytokine
Adult
Article
Controlled study
Cross-sectional study
Disease activity
Female
Human
Major clinical study
Personalized medicine
Systemic lupus erythematosus
Blood
Cluster analysis
Immunology
Middle aged
Systemic lupus erythematosus
Young adult
Adult
Autoantibodies
Cluster analysis
Cross-sectional studies
Cytokines
Female
Humans
Middle aged
Young adult
Anti-dsdna antibodies
Antiphospholipid antibodies
Autoantibodies
Cluster analysis
Cytokines
Interferon alpha
Interleukin 12p40
Interleukin 8
Personalized medicine
Subphenotypes
Systemic lupus erythematosus
Taxonomy
systemic
antinuclear
Antibodies
Lupus erythematosus
Rights
License
Abierto (Texto Completo)
Description
Summary:Background: Evidence supports the existence of different subphenotypes in systemic lupus erythematosus (SLE) and the pivotal role of cytokines and autoantibodies, which interact in a highly complex network. Thus, understanding how these complex nonlinear processes are connected and observed in real-life settings is a major challenge. Cluster approaches may assist in the identification of these subphenotypes, which represent such a phenomenon, and may contribute to the development of personalized medicine. Therefore, the relationship between autoantibody and cytokine clusters in SLE was analyzed. Methods: This was an exploratory study in which 67 consecutive women with established SLE were assessed. Clinical characteristics including disease activity, a 14-autoantibody profile, and a panel of 15 serum cytokines were measured simultaneously. Mixed-cluster methodology and bivariate analyses were used to define autoantibody and cytokine clusters and to identify associations between them and related variables. Results: First, three clusters of autoantibodies were defined: (1) neutral, (2) antiphospholipid antibodies (APLA)-dominant, and (3) anti-dsDNA/ENA-dominant. Second, eight cytokines showed levels above the threshold thus making possible to find 4 clusters: (1) neutral, (2) chemotactic, (3) G-CSF dominant, and (4) IFN?/Pro-inflammatory. Furthermore, the disease activity was associated with cytokine clusters, which, in turn, were associated with autoantibody clusters. Finally, when all biomarkers were included, three clusters were found: (1) neutral, (2) chemotactic/APLA, and (3) IFN/dsDNA, which were also associated with disease activity. Conclusion: These results support the existence of three SLE cytokine-autoantibody driven subphenotypes. They encourage the practice of personalized medicine, and support proof-of-concept studies. © 2017 The Author(s).